Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 645

1.

Role of MSC-derived galectin 3 in the AML microenvironment.

Ruvolo PP, Ruvolo VR, Burks JK, Qiu Y, Wang RY, Shpall EJ, Mirandola L, Hail N Jr, Zeng Z, McQueen T, Daver N, Post SM, Chiriva-Internati M, Kornblau SM, Andreeff M.

Biochim Biophys Acta. 2018 Apr 12;1865(7):959-969. doi: 10.1016/j.bbamcr.2018.04.005. [Epub ahead of print]

PMID:
29655803
2.

Liposomal Grb2 antisense oligodeoxynucleotide (BP1001) in patients with refractory or relapsed haematological malignancies: a single-centre, open-label, dose-escalation, phase 1/1b trial.

Ohanian M, Tari Ashizawa A, Garcia-Manero G, Pemmaraju N, Kadia T, Jabbour E, Ravandi F, Borthakur G, Andreeff M, Konopleva M, Lim M, Pierce S, O'Brien S, Alvarado Y, Verstovsek S, Wierda W, Kantarjian H, Cortes J.

Lancet Haematol. 2018 Apr;5(4):e136-e146. doi: 10.1016/S2352-3026(18)30021-8. Epub 2018 Mar 14.

PMID:
29550383
3.

Distinct protein signatures of acute myeloid leukemia bone marrow-derived stromal cells are prognostic for patient survival.

Kornblau SM, Ruvolo PP, Wang RY, Battula VL, Shpall EJ, Ruvolo VR, McQueen T, Qui Y, Zeng Z, Pierce S, Jacamo R, Yoo SY, Le PM, Sun J, Hail N Jr., Konopleva M, Andreeff M.

Haematologica. 2018 Mar 15. pii: haematol.2017.172429. doi: 10.3324/haematol.2017.172429. [Epub ahead of print]

4.

Predictive gene signatures determine tumor sensitivity to MDM2 inhibition.

Ishizawa J, Nakamaru K, Seki T, Tazaki K, Kojima K, Chachad D, Zhao R, Heese LE, Ma W, Ma MCJ, DiNardo CD, Pierce SA, Patel KP, Tse A, Davis RE, Rao A, Andreeff M.

Cancer Res. 2018 Feb 28. pii: canres.0949.2017. doi: 10.1158/0008-5472.CAN-17-0949. [Epub ahead of print]

PMID:
29490944
5.

Disruption of Wnt/β-Catenin Exerts Antileukemia Activity and Synergizes with FLT3 Inhibition in FLT3-Mutant Acute Myeloid Leukemia.

Jiang X, Mak PY, Mu H, Tao W, Mak DH, Kornblau S, Zhang Q, Ruvolo P, Burks JK, Zhang W, McQueen T, Pan R, Zhou H, Konopleva M, Cortes J, Liu Q, Andreeff M, Carter BZ.

Clin Cancer Res. 2018 Feb 20. doi: 10.1158/1078-0432.CCR-17-1556. [Epub ahead of print]

PMID:
29463558
6.

Discovery and functional implications of a miR-29b-1/miR-29a cluster polymorphism in acute myeloid leukemia.

Ngankeu A, Ranganathan P, Havelange V, Nicolet D, Volinia S, Powell BL, Kolitz JE, Uy GL, Stone RM, Kornblau SM, Andreeff M, Croce CM, Bloomfield CD, Garzon R.

Oncotarget. 2017 Dec 12;9(4):4354-4365. doi: 10.18632/oncotarget.23150. eCollection 2018 Jan 12.

7.

Outcomes with lower intensity therapy in TP53-mutated acute myeloid leukemia.

Boddu P, Kantarjian H, Ravandi F, Garcia-Manero G, Borthakur G, Andreeff M, Jabbour EJ, Benton CB, DiNardo CD, Konopleva M, Daver N, Patel K, Takahashi K, Kanagal-Shamanna R, Cortes J, Kadia T.

Leuk Lymphoma. 2018 Jan 17:1-4. doi: 10.1080/10428194.2017.1422864. [Epub ahead of print] No abstract available.

PMID:
29338567
8.

Co-occurrence of FLT3-TKD and NPM1 mutations defines a highly favorable prognostic AML group.

Boddu P, Kantarjian H, Borthakur G, Kadia T, Daver N, Pierce S, Andreeff M, Ravandi F, Cortes J, Kornblau SM.

Blood Adv. 2017 Aug 17;1(19):1546-1550. doi: 10.1182/bloodadvances.2017009019. eCollection 2017 Aug 22.

9.

Treated secondary acute myeloid leukemia: a distinct high-risk subset of AML with adverse prognosis.

Boddu P, Kantarjian HM, Garcia-Manero G, Ravandi F, Verstovsek S, Jabbour E, Borthakur G, Konopleva M, Bhalla KN, Daver N, DiNardo CD, Benton CB, Takahashi K, Estrov Z, Pierce SR, Andreeff M, Cortes JE, Kadia TM.

Blood Adv. 2017 Jul 19;1(17):1312-1323. doi: 10.1182/bloodadvances.2017008227. eCollection 2017 Jul 25.

10.

Anti-leukemia activity of NSC-743380 in SULT1A1-expressing acute myeloid leukemia cells is associated with inhibitions of cFLIP expression and PI3K/AKT/mTOR activities.

Huang X, Cao M, Wu S, Wang L, Hu J, Mehran RJ, Roth JA, Swisher SG, Wang RY, Kantarjian HM, Andreeff M, Sun X, Fang B.

Oncotarget. 2017 Nov 1;8(60):102150-102160. doi: 10.18632/oncotarget.22235. eCollection 2017 Nov 24.

11.

EANM guideline for radionuclide therapy with radium-223 of metastatic castration-resistant prostate cancer.

Poeppel TD, Handkiewicz-Junak D, Andreeff M, Becherer A, Bockisch A, Fricke E, Geworski L, Heinzel A, Krause BJ, Krause T, Mitterhauser M, Sonnenschein W, Bodei L, Delgado-Bolton RC, Gabriel M.

Eur J Nucl Med Mol Imaging. 2018 May;45(5):824-845. doi: 10.1007/s00259-017-3900-4. Epub 2017 Dec 12.

PMID:
29234845
12.

Synthetic Lethality of Combined Bcl-2 Inhibition and p53 Activation in AML: Mechanisms and Superior Antileukemic Efficacy.

Pan R, Ruvolo V, Mu H, Leverson JD, Nichols G, Reed JC, Konopleva M, Andreeff M.

Cancer Cell. 2017 Dec 11;32(6):748-760.e6. doi: 10.1016/j.ccell.2017.11.003.

PMID:
29232553
13.

Tumor Trp53 status and genotype affect the bone marrow microenvironment in acute myeloid leukemia.

Jacamo R, Davis RE, Ling X, Sonnylal S, Wang Z, Ma W, Zhang M, Ruvolo P, Ruvolo V, Wang RY, McQueen T, Lowe S, Zuber J, Kornblau SM, Konopleva M, Andreeff M.

Oncotarget. 2017 Jul 6;8(48):83354-83369. doi: 10.18632/oncotarget.19042. eCollection 2017 Oct 13.

14.

Anexelekto/MER tyrosine kinase inhibitor ONO-7475 arrests growth and kills FMS-like tyrosine kinase 3-internal tandem duplication mutant acute myeloid leukemia cells by diverse mechanisms.

Ruvolo PP, Ma H, Ruvolo VR, Zhang X, Mu H, Schober W, Hernandez I, Gallardo M, Khoury JD, Cortes J, Andreeff M, Post SM.

Haematologica. 2017 Dec;102(12):2048-2057. doi: 10.3324/haematol.2017.168856. Epub 2017 Sep 14.

15.

The Imipridone ONC201 Induces Apoptosis and Overcomes Chemotherapy Resistance by Up-Regulation of Bim in Multiple Myeloma.

Tu YS, He J, Liu H, Lee HC, Wang H, Ishizawa J, Allen JE, Andreeff M, Orlowski RZ, Davis RE, Yang J.

Neoplasia. 2017 Oct;19(10):772-780. doi: 10.1016/j.neo.2017.07.009. Epub 2017 Aug 30.

16.

Macrophages Facilitate Resistance to Anti-VEGF Therapy by Altered VEGFR Expression.

Dalton HJ, Pradeep S, McGuire M, Hailemichael Y, Ma S, Lyons Y, Armaiz-Pena GN, Previs RA, Hansen JM, Rupaimoole R, Gonzalez-Villasana V, Cho MS, Wu SY, Mangala LS, Jennings NB, Hu W, Langley R, Mu H, Andreeff M, Bar-Eli M, Overwijk W, Ram P, Lopez-Berestein G, Coleman RL, Sood AK.

Clin Cancer Res. 2017 Nov 15;23(22):7034-7046. doi: 10.1158/1078-0432.CCR-17-0647. Epub 2017 Aug 29.

PMID:
28855350
17.

Single-Cell Mass Cytometry of Acute Myeloid Leukemia and Leukemia Stem/Progenitor Cells.

Zeng Z, Konopleva M, Andreeff M.

Methods Mol Biol. 2017;1633:75-86. doi: 10.1007/978-1-4939-7142-8_5.

PMID:
28735481
18.

Vosaroxin in combination with decitabine in newly diagnosed older patients with acute myeloid leukemia or high-risk myelodysplastic syndrome.

Daver N, Kantarjian H, Garcia-Manero G, Jabbour E, Borthakur G, Brandt M, Pierce S, Vaughan K, Ning J, Nogueras González GM, Patel K, Jorgensen J, Pemmaraju N, Kadia T, Konopleva M, Andreeff M, DiNardo C, Cortes J, Ward R, Craig A, Ravandi F.

Haematologica. 2017 Oct;102(10):1709-1717. doi: 10.3324/haematol.2017.168732. Epub 2017 Jul 20.

19.

AML-induced osteogenic differentiation in mesenchymal stromal cells supports leukemia growth.

Battula VL, Le PM, Sun JC, Nguyen K, Yuan B, Zhou X, Sonnylal S, McQueen T, Ruvolo V, Michel KA, Ling X, Jacamo R, Shpall E, Wang Z, Rao A, Al-Atrash G, Konopleva M, Davis RE, Harrington MA, Cahill CW, Bueso-Ramos C, Andreeff M.

JCI Insight. 2017 Jul 6;2(13). pii: 90036. doi: 10.1172/jci.insight.90036. [Epub ahead of print]

20.

High-throughput profiling of signaling networks identifies mechanism-based combination therapy to eliminate microenvironmental resistance in acute myeloid leukemia.

Zeng Z, Liu W, Tsao T, Qiu Y, Zhao Y, Samudio I, Sarbassov DD, Kornblau SM, Baggerly KA, Kantarjian HM, Konopleva M, Andreeff M.

Haematologica. 2017 Sep;102(9):1537-1548. doi: 10.3324/haematol.2016.162230. Epub 2017 Jun 28.

21.

Combined targeting of STAT3 and STAT5: a novel approach to overcome drug resistance in chronic myeloid leukemia.

Gleixner KV, Schneeweiss M, Eisenwort G, Berger D, Herrmann H, Blatt K, Greiner G, Byrgazov K, Hoermann G, Konopleva M, Waliul I, Cumaraswamy AA, Gunning PT, Maeda H, Moriggl R, Deininger M, Lion T, Andreeff M, Valent P.

Haematologica. 2017 Sep;102(9):1519-1529. doi: 10.3324/haematol.2016.163436. Epub 2017 Jun 8.

22.

IKK inhibition by BMS-345541 suppresses breast tumorigenesis and metastases by targeting GD2+ cancer stem cells.

Battula VL, Nguyen K, Sun J, Pitner MK, Yuan B, Bartholomeusz C, Hail N, Andreeff M.

Oncotarget. 2017 Jun 6;8(23):36936-36949. doi: 10.18632/oncotarget.16294.

23.

Targeting mantle cell lymphoma metabolism and survival through simultaneous blockade of mTOR and nuclear transporter exportin-1.

Sekihara K, Saitoh K, Han L, Ciurea S, Yamamoto S, Kikkawa M, Kazuno S, Taka H, Kaga N, Arai H, Miida T, Andreeff M, Konopleva M, Tabe Y.

Oncotarget. 2017 May 23;8(21):34552-34564. doi: 10.18632/oncotarget.16602.

24.

A phase 1 clinical trial of single-agent selinexor in acute myeloid leukemia.

Garzon R, Savona M, Baz R, Andreeff M, Gabrail N, Gutierrez M, Savoie L, Mau-Sorensen PM, Wagner-Johnston N, Yee K, Unger TJ, Saint-Martin JR, Carlson R, Rashal T, Kashyap T, Klebanov B, Shacham S, Kauffman M, Stone R.

Blood. 2017 Jun 15;129(24):3165-3174. doi: 10.1182/blood-2016-11-750158. Epub 2017 Mar 23.

PMID:
28336527
25.

Combined inhibition of β-catenin and Bcr-Abl synergistically targets tyrosine kinase inhibitor-resistant blast crisis chronic myeloid leukemia blasts and progenitors in vitro and in vivo.

Zhou H, Mak PY, Mu H, Mak DH, Zeng Z, Cortes J, Liu Q, Andreeff M, Carter BZ.

Leukemia. 2017 Oct;31(10):2065-2074. doi: 10.1038/leu.2017.87. Epub 2017 Mar 21.

26.

A phase 1/2 study of chemosensitization with plerixafor plus G-CSF in relapsed or refractory acute myeloid leukemia.

Uy GL, Rettig MP, Stone RM, Konopleva MY, Andreeff M, McFarland K, Shannon W, Fletcher TR, Reineck T, Eades W, Stockerl-Goldstein K, Abboud CN, Jacoby MA, Westervelt P, DiPersio JF.

Blood Cancer J. 2017 Mar 10;7(3):e542. doi: 10.1038/bcj.2017.21. No abstract available.

27.

Jab1/Csn5-Thioredoxin Signaling in Relapsed Acute Monocytic Leukemia under Oxidative Stress.

Zhou F, Pan Y, Wei Y, Zhang R, Bai G, Shen Q, Meng S, Le XF, Andreeff M, Claret FX.

Clin Cancer Res. 2017 Aug 1;23(15):4450-4461. doi: 10.1158/1078-0432.CCR-16-2426. Epub 2017 Mar 7.

28.

Focal Adhesion Kinase as a Potential Target in AML and MDS.

Carter BZ, Mak PY, Wang X, Yang H, Garcia-Manero G, Mak DH, Mu H, Ruvolo VR, Qiu Y, Coombes K, Zhang N, Ragon B, Weaver DT, Pachter JA, Kornblau S, Andreeff M.

Mol Cancer Ther. 2017 Jun;16(6):1133-1144. doi: 10.1158/1535-7163.MCT-16-0719. Epub 2017 Mar 7.

PMID:
28270436
29.

More than 1 TP53 abnormality is a dominant characteristic of pure erythroid leukemia.

Montalban-Bravo G, Benton CB, Wang SA, Ravandi F, Kadia T, Cortes J, Daver N, Takahashi K, DiNardo C, Jabbour E, Borthakur G, Konopleva M, Pierce S, Bueso-Ramos C, Patel K, Kornblau S, Kantarjian H, Young KH, Garcia-Manero G, Andreeff M.

Blood. 2017 May 4;129(18):2584-2587. doi: 10.1182/blood-2016-11-749903. Epub 2017 Feb 28. No abstract available.

PMID:
28246192
30.

Mesenchymal stromal cells for the delivery of oncolytic viruses in gliomas.

Parker Kerrigan BC, Shimizu Y, Andreeff M, Lang FF.

Cytotherapy. 2017 Apr;19(4):445-457. doi: 10.1016/j.jcyt.2017.02.002. Epub 2017 Feb 21. Review.

31.

PTEN status is a crucial determinant of the functional outcome of combined MEK and mTOR inhibition in cancer.

Milella M, Falcone I, Conciatori F, Matteoni S, Sacconi A, De Luca T, Bazzichetto C, Corbo V, Simbolo M, Sperduti I, Benfante A, Del Curatolo A, Cesta Incani U, Malusa F, Eramo A, Sette G, Scarpa A, Konopleva M, Andreeff M, McCubrey JA, Blandino G, Todaro M, Stassi G, De Maria R, Cognetti F, Del Bufalo D, Ciuffreda L.

Sci Rep. 2017 Feb 21;7:43013. doi: 10.1038/srep43013.

32.

The authors reply.

Güldner A, Braune A, Ball L, Leme Silva P, Samary C, Insorsi A, Huhle R, Rentzsch I, Becker C, Oehme L, Andreeff M, Vidal Melo MF, Winkler T, Pelosi P, Rieken Macedo Rocco P, Kotzerke J, Gama de Abreu M.

Crit Care Med. 2017 Mar;45(3):e328-e329. doi: 10.1097/CCM.0000000000002225. No abstract available.

33.

The novel BMI-1 inhibitor PTC596 downregulates MCL-1 and induces p53-independent mitochondrial apoptosis in acute myeloid leukemia progenitor cells.

Nishida Y, Maeda A, Kim MJ, Cao L, Kubota Y, Ishizawa J, AlRawi A, Kato Y, Iwama A, Fujisawa M, Matsue K, Weetall M, Dumble M, Andreeff M, Davis TW, Branstrom A, Kimura S, Kojima K.

Blood Cancer J. 2017 Feb 17;7(2):e527. doi: 10.1038/bcj.2017.8.

34.

FZR1 loss increases sensitivity to DNA damage and consequently promotes murine and human B-cell acute leukemia.

Ishizawa J, Sugihara E, Kuninaka S, Mogushi K, Kojima K, Benton CB, Zhao R, Chachad D, Hashimoto N, Jacamo RO, Qiu Y, Yoo SY, Okamoto S, Andreeff M, Kornblau SM, Saya H.

Blood. 2017 Apr 6;129(14):1958-1968. doi: 10.1182/blood-2016-07-726216. Epub 2017 Jan 31.

35.

Bone Marrow Adipocytes Facilitate Fatty Acid Oxidation Activating AMPK and a Transcriptional Network Supporting Survival of Acute Monocytic Leukemia Cells.

Tabe Y, Yamamoto S, Saitoh K, Sekihara K, Monma N, Ikeo K, Mogushi K, Shikami M, Ruvolo V, Ishizawa J, Hail N Jr, Kazuno S, Igarashi M, Matsushita H, Yamanaka Y, Arai H, Nagaoka I, Miida T, Hayashizaki Y, Konopleva M, Andreeff M.

Cancer Res. 2017 Mar 15;77(6):1453-1464. doi: 10.1158/0008-5472.CAN-16-1645. Epub 2017 Jan 20.

36.

Eradication of CML stem cells.

Carter BZ, Andreeff M.

Oncoscience. 2016 Nov 23;3(11-12):313-315. doi: 10.18632/oncoscience.327. eCollection 2016. No abstract available.

37.

Antileukemia Efficacy and Mechanisms of Action of SL-101, a Novel Anti-CD123 Antibody Conjugate, in Acute Myeloid Leukemia.

Han L, Jorgensen JL, Brooks C, Shi C, Zhang Q, Nogueras González GM, Cavazos A, Pan R, Mu H, Wang SA, Zhou J, Ai-Atrash G, Ciurea SO, Rettig M, DiPersio JF, Cortes J, Huang X, Kantarjian HM, Andreeff M, Ravandi F, Konopleva M.

Clin Cancer Res. 2017 Jul 1;23(13):3385-3395. doi: 10.1158/1078-0432.CCR-16-1904. Epub 2017 Jan 17.

PMID:
28096272
38.

Relapse risk and survival in patients with FLT3 mutated acute myeloid leukemia undergoing stem cell transplantation.

Gaballa S, Saliba R, Oran B, Brammer JE, Chen J, Rondon G, Alousi AM, Kebriaei P, Marin D, Popat UR, Andersson BS, Shpall EJ, Jabbour E, Daver N, Andreeff M, Ravandi F, Cortes J, Patel K, Champlin RE, Ciurea SO.

Am J Hematol. 2017 Apr;92(4):331-337. doi: 10.1002/ajh.24632. Epub 2017 Feb 13.

39.

Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab.

Abaza Y, Kantarjian H, Garcia-Manero G, Estey E, Borthakur G, Jabbour E, Faderl S, O'Brien S, Wierda W, Pierce S, Brandt M, McCue D, Luthra R, Patel K, Kornblau S, Kadia T, Daver N, DiNardo C, Jain N, Verstovsek S, Ferrajoli A, Andreeff M, Konopleva M, Estrov Z, Foudray M, McCue D, Cortes J, Ravandi F.

Blood. 2017 Mar 9;129(10):1275-1283. doi: 10.1182/blood-2016-09-736686. Epub 2016 Dec 21.

40.

Targeting autophagy to overcome chemoresistance in acute myleogenous leukemia.

Piya S, Andreeff M, Borthakur G.

Autophagy. 2017 Jan 2;13(1):214-215. doi: 10.1080/15548627.2016.1245263. Epub 2016 Oct 31.

41.

Editorial.

Cruz CRY, Andreeff M, Barrett J.

Cytotherapy. 2016 Nov;18(11):1349-1350. doi: 10.1016/j.jcyt.2016.09.004. Epub 2016 Sep 26. No abstract available.

PMID:
27686830
42.

Buparlisib, a PI3K inhibitor, demonstrates acceptable tolerability and preliminary activity in a phase I trial of patients with advanced leukemias.

Ragon BK, Kantarjian H, Jabbour E, Ravandi F, Cortes J, Borthakur G, DeBose L, Zeng Z, Schneider H, Pemmaraju N, Garcia-Manero G, Kornblau S, Wierda W, Burger J, DiNardo CD, Andreeff M, Konopleva M, Daver N.

Am J Hematol. 2017 Jan;92(1):7-11. doi: 10.1002/ajh.24568. Epub 2016 Dec 7.

43.

Persistence of minimal residual disease assessed by multiparameter flow cytometry is highly prognostic in younger patients with acute myeloid leukemia.

Ravandi F, Jorgensen J, Borthakur G, Jabbour E, Kadia T, Pierce S, Brandt M, Wang S, Konoplev S, Wang X, Huang X, Daver N, DiNardo C, Andreeff M, Konopleva M, Estrov Z, Garcia-Manero G, Cortes J, Kantarjian H.

Cancer. 2017 Feb 1;123(3):426-435. doi: 10.1002/cncr.30361. Epub 2016 Sep 22.

44.

Combined targeting of BCL-2 and BCR-ABL tyrosine kinase eradicates chronic myeloid leukemia stem cells.

Carter BZ, Mak PY, Mu H, Zhou H, Mak DH, Schober W, Leverson JD, Zhang B, Bhatia R, Huang X, Cortes J, Kantarjian H, Konopleva M, Andreeff M.

Sci Transl Med. 2016 Sep 7;8(355):355ra117. doi: 10.1126/scitranslmed.aag1180.

45.

Discovery and clinical introduction of first-in-class imipridone ONC201.

Allen JE, Kline CL, Prabhu VV, Wagner J, Ishizawa J, Madhukar N, Lev A, Baumeister M, Zhou L, Lulla A, Stogniew M, Schalop L, Benes C, Kaufman HL, Pottorf RS, Nallaganchu BR, Olson GL, Al-Mulla F, Duvic M, Wu GS, Dicker DT, Talekar MK, Lim B, Elemento O, Oster W, Bertino J, Flaherty K, Wang ML, Borthakur G, Andreeff M, Stein M, El-Deiry WS.

Oncotarget. 2016 Nov 8;7(45):74380-74392. doi: 10.18632/oncotarget.11814. Review.

46.

Targeting FLT3-ITD signaling mediates ceramide-dependent mitophagy and attenuates drug resistance in AML.

Dany M, Gencer S, Nganga R, Thomas RJ, Oleinik N, Baron KD, Szulc ZM, Ruvolo P, Kornblau S, Andreeff M, Ogretmen B.

Blood. 2016 Oct 13;128(15):1944-1958. Epub 2016 Aug 18.

47.

The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice.

Townsend EC, Murakami MA, Christodoulou A, Christie AL, Köster J, DeSouza TA, Morgan EA, Kallgren SP, Liu H, Wu SC, Plana O, Montero J, Stevenson KE, Rao P, Vadhi R, Andreeff M, Armand P, Ballen KK, Barzaghi-Rinaudo P, Cahill S, Clark RA, Cooke VG, Davids MS, DeAngelo DJ, Dorfman DM, Eaton H, Ebert BL, Etchin J, Firestone B, Fisher DC, Freedman AS, Galinsky IA, Gao H, Garcia JS, Garnache-Ottou F, Graubert TA, Gutierrez A, Halilovic E, Harris MH, Herbert ZT, Horwitz SM, Inghirami G, Intlekofer AM, Ito M, Izraeli S, Jacobsen ED, Jacobson CA, Jeay S, Jeremias I, Kelliher MA, Koch R, Konopleva M, Kopp N, Kornblau SM, Kung AL, Kupper TS, LeBoeuf NR, LaCasce AS, Lees E, Li LS, Look AT, Murakami M, Muschen M, Neuberg D, Ng SY, Odejide OO, Orkin SH, Paquette RR, Place AE, Roderick JE, Ryan JA, Sallan SE, Shoji B, Silverman LB, Soiffer RJ, Steensma DP, Stegmaier K, Stone RM, Tamburini J, Thorner AR, van Hummelen P, Wadleigh M, Wiesmann M, Weng AP, Wuerthner JU, Williams DA, Wollison BM, Lane AA, Letai A, Bertagnolli MM, Ritz J, Brown M, Long H, Aster JC, Shipp MA, Griffin JD, Weinstock DM.

Cancer Cell. 2016 Jul 11;30(1):183. doi: 10.1016/j.ccell.2016.06.008. Epub 2016 Jul 11. No abstract available.

48.

Peripheral blood blast clearance is an independent prognostic factor for survival and response to acute myeloid leukemia induction chemotherapy.

Short NJ, Benton CB, Chen HC, Qiu P, Gu L, Pierce S, Brandt M, Maiti A, Min TL, Naqvi K, Quintas-Cardama A, Konopleva M, Kadia T, Cortes J, Garcia-Manero G, Ravandi F, Jabbour E, Kantarjian H, Andreeff M.

Am J Hematol. 2016 Dec;91(12):1221-1226. doi: 10.1002/ajh.24500. Epub 2016 Aug 29.

49.

Bone marrow niche-mediated survival of leukemia stem cells in acute myeloid leukemia: Yin and Yang.

Zhou HS, Carter BZ, Andreeff M.

Cancer Biol Med. 2016 Jun;13(2):248-59. doi: 10.20892/j.issn.2095-3941.2016.0023.

50.

[Therapy of bone metastases with radium-223. German guidelines].

Pöppel TD, Andreeff M, Becherer A, Bockisch A, Fricke E, Geworski L, Heinzel A, Krause BJ, Krause T, Mitterhauser M, Scheidhauer K, Schenck M, Sonnenschein W, Gabriel M.

Nuklearmedizin. 2016 Sep 26;55(5):177-86. doi: 10.3413/Nukmed-2016050001. Epub 2016 Jul 15. German.

PMID:
27417067

Supplemental Content

Loading ...
Support Center